As a leading pharmaceutical company in clinical trials, AstraZeneca welcomes British Trade Commissioner for Europe Chris Barton
Vienna (OTS) –
- Chris Barton, British Trade Commissioner for Europe, visits AstraZeneca Austria
- AstraZeneca Austria: Leader in clinical trials and breast cancer research
- Innovative development thanks to groundbreaking collaborations using the example of the ABCSG (Austrian Breast and Colorectal Cancer Study Group)
Chris Barton, British Trade Commissioner for Europe, visited pharmaceutical company AstraZeneca on March 19. The company is a leader in clinical studies in Austria. An important focus is on breast cancer research, in which groundbreaking results have been presented. The success is based, among other things, on collaboration and cooperation with well-known research institutes and institutions such as the ABCSG. The prominent visit, which was received together with the ABCSG at the new AstraZeneca site, emphasizes the importance for research and development of medicines in Austria. +++
With currently 13 new studies since the beginning of 2023 to date, AstraZeneca continues to be a leader in clinical studies in Austria. In oncology in particular, the innovative company is leading the way in clinical studies on breast, ovarian and lung cancer.
The British Trade Commissioner Chris Barton welcomes the important contribution of AstraZeneca, which it is making as a British-Swedish company in Austria for the life sciences sector. Research and development activities play a crucial role for Great Britain, which occupies a leadership position in the life science sector. “The UK is a global life sciences hub, second only to the US and a leader in Europe. More than 5,600 life sciences companies already operate in the UK, working with governments, academia and industries abroad to drive innovation in the sector. AstraZeneca is a leading biopharmaceutical company in the UK and I look forward to deepening our partnership with Austrian regulators and scientists to bring life-changing medicines to patients.”
emphasizes Chris Barton, His Majesty’s Trade Commissioner for Europe, Department for Business and Trade (DBT).
AstraZeneca is making an important contribution to the life sciences sector
“Research into breast cancer, the most common cancer in women, is of enormous importance. Our leading role with a total of 13 new clinical studies, including 8 in the field of breast cancer, in Austria last year shows our commitment to the development of innovative therapies that can significantly improve patients’ lives. Our focus is on areas with high medical needs. For us, collaboration with medical research institutions is an essential part of this.”
, emphasizes Filippo Fontana, Managing Director of AstraZeneca Austria. Also Univ.-Prof. Dr. Michael Gnant, President of the ABCSG, emphasizes the importance of cooperation for research in Austria: “Collaboration between academic centers and the pharmaceutical industry plays a central role in advancing innovative treatment methods. Through these partnerships – transparent and on an equal footing – we can ensure that promising approaches quickly find their way into clinical practice and thus improve the lives of patients.”
Patients primarily benefit from the clinical studies, but also the Austrian healthcare system and Austria as a research location. Because every euro invested by the pharmaceutical industry in clinical research generates almost twice as much (1.95 euros) for the Austrian economy.
„A healthy society on a healthy planet“
True to the motto: “A healthy society on a healthy planet,” AstraZeneca contributes not only to the economy and medical research, but also to environmental protection. To this end, AstraZeneca has already implemented numerous measures, such as moving to an office building with a sustainable energy supply and switching to a fully electric car fleet.
Find out more at: https://value.astrazeneca.at/
About the ABCSG
The ABCSG (Austrian Breast and Colorectal Cancer Study Group) is Austria’s largest and best-known academic research organization that carries out international clinical studies on breast, colon and, since 2013, projects on pancreatic cancer and is successfully active in the field of translational cancer research. Almost 40 years ago by some enthusiasts under the leadership of em. Univ.-Prof. Dr. Founded by Raimund Jakesz with the aim of carrying out systematic breast cancer research in Austria, the ABCSG has now grown into an internationally networked organization that is responsible not only for the scientific clinical but also the operational implementation of global studies.
The primary goal of the ABCSG is to standardize diagnostics, therapy and follow-up treatment throughout Austria and to provide patients with the latest and best possible therapy. Since its founding in 1984, over 29,000 patients worldwide have participated in ABCSG studies. The results have received the greatest international scientific recognition and have made a significant contribution to improving the patients’ chances of recovery and survival.
In addition, the further training of medical professionals by organizing symposiums, congresses, webinars and e-learning and the publication of scientific articles is the second pillar of their work and a major concern of the ABCSG. Every year, numerous publications on research results from ABCSG members appear in various high-ranking medical journals. In addition to the academic publications of recent clinical studies, the ABCSG also acts as publisher of the specialist magazine krebs:hilfe!
Further information can be found at www.abcsg.org or you can follow us on LinkedIn @Austrian Breast & Colorectal Cancer Study Group (ABCSG) under #abcsg, on Instagram @abcsgVienna or X/Twitter @ABCSGVienna
About AstraZeneca
AstraZeneca is a global, research-focused biopharmaceutical company. The company develops, produces and sells innovative medicines primarily in the therapeutic areas of oncology, cardiovascular, kidney and metabolic diseases, respiratory, infectious and autoimmune diseases as well as rare diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AstraZeneca Austria is one of the leading research-based pharmaceutical companies on the domestic market and is number 1 in clinical studies in Austria. The company makes an indispensable contribution to the development of therapies and the cure or alleviation of diseases – for example by treating four of the five deadliest diseases. The company creates highly qualified jobs, promotes talent and offers scope for the development of its employees. AstraZeneca is also committed to a healthy society on a healthy planet, with the goal of net-zero emissions healthcare.
Further information can be found at www.astrazeneca.at or follow us on LinkedIn @AstraZeneca under #astrazenecaaustria and on Facebook/Instagram (@astrazenecaaustria).
Questions & Contact:
ABCSG – Austrian Breast & Colorectal Cancer Study Group
Association for the prevention and treatment of malignant diseases
Mag. Hedwig Schulz
Communication Manager
hedwig.schulz@abcsg.at
+43 1 4089230-12, +43 664 4379837
AstraZeneca Austria GmbH
Simone Farina, Bakk. comm.
External Communication Lead
simone.farina@astrazeneca.com
+43 664 88145 915